Author: Tursunova Balkadisha
Translator: Turarova Aiym
Copy editor: Kigbaeva Kamila, Issabayeva Madina
The technology for obtaining human immunoglobulins was developed by the company of the holding "Natimbio", the administration will be intravenous. The drug "Biogam" has already passed the first phase of clinical trials.
The drug containing antibodies to coronavirus infection will be manufactured on the basis of plasma from donors who have suffered Covid-19 infection. It is noted that companies will soon be able to bring an effective and safe drug to the domestic market.
According to the latest data, more than 493 thousand cases of coronavirus infection have been detected in Russia alone, more than 252 thousand patients have already been cured, and another 6,358 have died as a result of complications.
At the moment, there is no specific drug in the world that targets the pathogen of the coronavirus. Scientists are still establishing all the relationships between the spread, course and outcome of the disease. The main goal is prevention, maximum abstinence from contact with society and protection of themselves from possible infection.
Source: https://radiosputnik.ria.ru/
